文章摘要

文章信息/Info

Title:: Efficacy and safety of Warfarin in aged patients with nonvalvular atrial fibrillation

作者:: 王瑞¹; 2; 颜虹¹; 闫自强²; 王忻欣²; 1.西安交通大学医学院公共卫生与统计学教研室, 陕西西安 710036;2.解放军451医院干部病房, 陕西西安 710054

Author(s):: WANG Rui¹; 2; YAN Hong¹; YAN Ziqiang²; WANG Xinxin²; 1.Sanitation and statistic depatemeng of Xi’an Jiaotong University Xi’an 710036，Shaanxi，China,2.Department of Geriatrics, PLA 451 Hospital, Xi’an 710054, Shaanxi, China

关键词:: 心房颤动; 华法令; 治疗

Keywords:: Warfarin ; Atrial fibrillation ; Therapy

分类号:: R541.4

DOI:: -

文献标识码:: A

摘要:: 目的观察华发令预防高龄非瓣膜病心房颤动（房颤）患者血栓栓塞的效果及安全性。方法选择2002年1月~2006年1月120例在我科住院的年龄≥75岁房颤患者，随机分为4组，A、B、C 3组华发令口服剂量随国际准化比率（INR）调整， A组INR维持在1.5～2.0；B组INR维持在2.0～3.0；C组INR维持在1.5～2.0的同时给予阿司匹林100 mg/d口服；D组给予阿司匹林100～200 mg/d口服，随访时间18～48（32±8）月，随访内容使用统一表格，记录各项化验及其他辅助检查结果、终点事件发生时间等。结果 A组栓塞事件1例（3%）， D组6例（20%）， B、C组无1例；A、D组出血事件各发生1例（3%）， B组5例（17%），C组7例（23%）；D组死亡7例，C组死亡1例，P<0.05。结论华发令抗凝强度INR为1.5～2.0时对预防高龄房颤患者血栓栓塞安全、有效，可供临床选择。

Abstract:: AIM To investigate the efficacy and safety of Warfarin in elderly patients with chronic nonvalvular atrial fibrillation. METHODS One hundred and twenty cases of aged patients were divided into four groups and were followed up for 32 8 months. Different doses of Warfarin were given to groups A, group B and group C according to International Normalized Ratio (INR). The INR was 1.5～2.0 in group A, 2.0～3.0 in group B, and 1.5～2.0 in group C plus aspirin 100 mg/day. D group was given aspirin 100～200 mg/day. The results of biochemical and supplementary tests and the terminal occurrences were documented. RESULTS One case of thrombosis occurred in group A (3%), 6 cases in group D (20%) and none in group B and group C. One case of hemorrhage occurred respectively in group A and group D (3%), 5 cases in group B (17%) and 7 cases in group C (23%). Seven cases of death occurred in group D and one case in group C（P<0.05）. CONCLUSION Warfarin is safe and effective when INR is between 1.5～2.0 in elderly patients with nonvalvular atrial fibrillation.

参考文献/References

［1］ Frisoni GB, Fratiglioni L, Fastbom J, et al. Mild cognitive impairment in the popnlation and physical health: data on 1 435 individuals aged 75 to 95［J］. J Gerontol Biol Sci Med Sci， 2000, 55（6）：M322-M328.

［2］杜晰，胡蓉，康俊萍，等.心房颤动门诊病例的调查［J］.中国心脏起博与心电生理杂志，2004，18（6）：438-440.

［3］ Hirsh J, Fuster V，Ansell J，et al. American Heart Association /American College of Cardiology Foundation guide to atrial fibrillation therapy［J］. J Am Coll Cardiol，2003，41（9）：1633-1652.

［4］葛堪忆，曾辉，佘飞. 540例持续性心房颤动患者华发令抗凝治疗安全性的临床观察［J］. 中国心脏起博与心电生理杂志，2004，18（6）：435-437.

［5］ Gage BF，Boechler M，Doggette AL，et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation［J］. Stroke，2000，31（4）：822-827.

我们的网站为什么显示成这样？

华发令预防高龄非瓣膜病房颤血栓栓塞的效果及安全性(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics